Multistage Vector Delivery of Sulindac and Silymarin for Prevention of Colon Cancer | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
scientific articles

Multistage Vector Delivery of Sulindac and Silymarin for Prevention of Colon Cancer

key information

source: Colloids and surfaces. B, Biointerfaces

year: 2015

authors: Scavo M P, Gentile E, Wolfram J, Gu J, Barone M, Evangelopoulos M, Martinez J O, Liu X, Celia C, Tasciotti E, Vilar E, Shen H


Familial adenomatous polyposis (FAP) is an inherited condition secondary to germline mutations in the APC gene, thus resulting in the formation of hundreds of colonic adenomas that eventually progress into colon cancer. Surgical removal of the colon remains the only treatment option to avoid malignancy, as long-term exposure to chemopreventive agents such as sulindac (a non-steroidal anti-inflammatory drug) and silymarin (phytoestrogen) is not feasible. Here, we have developed a multistage silicon-based drug delivery platform for sulindac and silymarin that preferentially interacts with colon cancer cells as opposed to normal intestinal mucosa. Preferential binding and internalization of these drugs into colon cancer cells was obtained using a targeting strategy against the protein meprin A, which we demonstrate is overexpressed in human colon cancer cells and in the small intestine of Apc(Min/+) mice. We propose that this delivery system could potentially be used to reduce drug-induced side effects in FAP patients, thus enabling long-term prevention of adenoma formation.

organization: Houston Methodist Research Institute, The University of Texas MD Anderson Cancer Center, National Center for Nanoscience & Technology of China, University of Bari, University G. d'Annunzio of Chieti, Weill Cornell Medical College

DOI: 10.1016/j.colsurfb.2015.10.005

read more full text source

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.